News

The FDA declined to approve one of biotech’s most closely watched cancer drugs

Marketwatch

The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.

Read the full Veytics brief

We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.